NO20010140L - Kjemotakse-inhiberende protein av Staphylococcus (CHIPS) og dets anvendelse - Google Patents

Kjemotakse-inhiberende protein av Staphylococcus (CHIPS) og dets anvendelse

Info

Publication number
NO20010140L
NO20010140L NO20010140A NO20010140A NO20010140L NO 20010140 L NO20010140 L NO 20010140L NO 20010140 A NO20010140 A NO 20010140A NO 20010140 A NO20010140 A NO 20010140A NO 20010140 L NO20010140 L NO 20010140L
Authority
NO
Norway
Prior art keywords
staphylococcus
chips
chemotaxin
inhibiting protein
treatment
Prior art date
Application number
NO20010140A
Other languages
English (en)
Other versions
NO20010140D0 (no
Inventor
Johannes Antonius Gerar Strijp
Cornelis Petrus Maria V Kessel
Original Assignee
Jari Pharmaceuticals Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jari Pharmaceuticals Bv filed Critical Jari Pharmaceuticals Bv
Publication of NO20010140D0 publication Critical patent/NO20010140D0/no
Publication of NO20010140L publication Critical patent/NO20010140L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Den foreliggende oppfinnelse vedrører et nytt protein fra bakterien Staphylococcus aureus med immunomodulerende egenskaper. Oppfinnelsen vedrører videre fremstillingen av en terapeutisk sammensetning som generell inflammasjonsin- hibitor og for behandlingen av AIDS, og også anvendelsen av antistoffer mot CHIPS for behandlingen av Staphylococcus- infeksjoner.
NO20010140A 1998-07-10 2001-01-09 Kjemotakse-inhiberende protein av Staphylococcus (CHIPS) og dets anvendelse NO20010140L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1009614 1998-07-10
PCT/NL1999/000442 WO2000002913A1 (en) 1998-07-10 1999-07-12 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use

Publications (2)

Publication Number Publication Date
NO20010140D0 NO20010140D0 (no) 2001-01-09
NO20010140L true NO20010140L (no) 2001-03-01

Family

ID=19767471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010140A NO20010140L (no) 1998-07-10 2001-01-09 Kjemotakse-inhiberende protein av Staphylococcus (CHIPS) og dets anvendelse

Country Status (22)

Country Link
US (2) US20050143307A1 (no)
EP (1) EP1095059B1 (no)
JP (1) JP2002520336A (no)
KR (1) KR20010053290A (no)
CN (1) CN1309662A (no)
AT (1) ATE328898T1 (no)
AU (1) AU4935999A (no)
BG (1) BG105120A (no)
BR (1) BR9911944A (no)
CA (1) CA2333898A1 (no)
CY (1) CY1105343T1 (no)
DE (1) DE69931784T2 (no)
DK (1) DK1095059T3 (no)
ES (1) ES2270609T3 (no)
HU (1) HUP0102975A2 (no)
IL (1) IL140768A0 (no)
NO (1) NO20010140L (no)
NZ (1) NZ509051A (no)
PL (1) PL345452A1 (no)
PT (1) PT1095059E (no)
WO (1) WO2000002913A1 (no)
ZA (1) ZA200100092B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1095059T3 (da) * 1998-07-10 2006-10-02 Alligator Bioscience Ab Publ Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse
EP1118663A1 (en) 2000-01-07 2001-07-25 Universiteit Utrecht Nucleic acids encoding chemotaxis inhibitory polypeptides
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2003006048A1 (en) * 2001-07-11 2003-01-23 Jari Pharmaceuticals B.V. Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds
DE602004031836D1 (de) * 2003-07-08 2011-04-28 Umc Utrecht Holding Bv Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
EP1586583A3 (en) * 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
US20090186111A1 (en) 2004-07-26 2009-07-23 Zeev Trainin Novel Bacteria and Pharmaceutically Active Products Obtained Therefrom
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772584A (en) * 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
EP0669989A1 (en) * 1991-08-22 1995-09-06 Washington University Polynucleotide probes for salmonella
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5514455A (en) * 1994-07-08 1996-05-07 Union Carbide Chemicals & Plastics Technology Corporation Film extruded from an in situ blend of ethylene copolymers
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
DK1095059T3 (da) * 1998-07-10 2006-10-02 Alligator Bioscience Ab Publ Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse
JP3722194B2 (ja) * 1999-05-20 2005-11-30 セイコーエプソン株式会社 画像表示システム
EP1118663A1 (en) * 2000-01-07 2001-07-25 Universiteit Utrecht Nucleic acids encoding chemotaxis inhibitory polypeptides
US6958213B2 (en) * 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) * 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
US7262012B2 (en) * 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations

Also Published As

Publication number Publication date
NZ509051A (en) 2003-01-31
PL345452A1 (en) 2001-12-17
EP1095059A1 (en) 2001-05-02
US20080242605A1 (en) 2008-10-02
DK1095059T3 (da) 2006-10-02
ES2270609T3 (es) 2007-04-01
BG105120A (en) 2001-11-30
US20050143307A1 (en) 2005-06-30
PT1095059E (pt) 2006-10-31
KR20010053290A (ko) 2001-06-25
AU4935999A (en) 2000-02-01
NO20010140D0 (no) 2001-01-09
EP1095059B1 (en) 2006-06-07
ZA200100092B (en) 2001-07-23
WO2000002913A1 (en) 2000-01-20
CN1309662A (zh) 2001-08-22
IL140768A0 (en) 2002-02-10
JP2002520336A (ja) 2002-07-09
DE69931784T2 (de) 2007-06-14
DE69931784D1 (de) 2006-07-20
BR9911944A (pt) 2001-09-25
HUP0102975A2 (hu) 2001-11-28
WO2000002913B1 (en) 2000-03-30
CA2333898A1 (en) 2000-01-20
ATE328898T1 (de) 2006-06-15
CY1105343T1 (el) 2010-03-03

Similar Documents

Publication Publication Date Title
SE0102315D0 (sv) Compounds
HUP0400446A2 (hu) Azitromicin kristályformái
AU2001278003A1 (en) Bacteriophage having multiple host range
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
BR0014470A (pt) Inibidores de fab i
GEP20094834B (en) Macrolides, pharmaceutical compositions containing them and their use for treatment of bacterial infections
ATE255589T1 (de) Kristallin form i von clarithromycin
DK1200418T3 (da) Nematodicide trifluorbutener
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
ATE433963T1 (de) Fab-i inhibitoren
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
CY1105343T1 (el) Σταφυλοκοκκικη πρωτεϊνη αναστολης του χημειοτακτισμου (chips) και η χρηση αυτης
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
NO971625L (no) Nye peptider med immunomodulatoriske effekter
ATE222115T1 (de) Verbesserung der antibakteriellen wirkung von oxazolidinon durch arginin derivate
DK1057828T3 (da) Orale trovafloxacin-suspensioner
NO20044549L (no) Bisykliske 6-alkaliden-penemer som beta-laktamaseinhibitorer
DE59903759D1 (de) Ektoparasitizide mittel
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
NO20044550L (no) Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer
SE9904128D0 (sv) Novel compounds
DE60326710D1 (de) Trizyklische antibakterielle makrolidderivate